Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: Results from the 24-week randomised, double-blind, placebocontrolled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

Annals of the Rheumatic Diseases

Volumn 76, Issue 1, 2017, Pages 79-87

  Mease, Philip J ^a,h   Van Der Heijde, Désirée ^b   Ritchlin, Christopher T ^c   Okada, Masato ^d   Cuchacovich, Raquel S ^e,f   Shuler, Catherine L ^e   Lin, Chen Yen ^e   Braun, Daniel K ^e   Lee, Chin H ^e   Gladman, Dafna D ^g  

^a UNIVERSITY OF WASHINGTON   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^e ELI LILLY AND COMPANY   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

^h Rheumatology Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; IXEKIZUMAB; PLACEBO; ANTIRHEUMATIC AGENT; INTERLEUKIN 17; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BACKACHE; BRONCHITIS; CANDIDIASIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CYTOPENIA; DEPRESSION; DIARRHEA; DISABILITY; DISEASE ACTIVITY; DISEASE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MUSCLE SPASM; NAUSEA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; TREATMENT OUTCOME;

ADALIMUMAB; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN-17; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84984629205     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209709     Document Type: Article

References (34)

1. Gladman DD. Psoriatic arthritis. Dermatol Ther 2009;22: 40-55.
2. de Vlam K, Gottlieb AB, Mease PJ. Current concepts in psoriatic arthritis: Pathogenesis and management. Acta Derm Venereol 2014;94: 627-34.
3. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl 2): Ii14-17.
4. Leung YY, Tam LS, Kun EW, et al. Psoriatic arthritis as a distinct disease entity. J Postgrad Med 2007;53: 63-71.
5. Raychaudhuri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 2013;44: 183-93.
6. Jandus C, Bioley G, Rivals JP, et al. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 2008;58: 2307-17.
7. Kagami S, Rizzo HL, Lee JJ, et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010;130: 1373-83.
8. Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 2011;187: 490-500.
9. Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum 2012;64: 99-109.
10. Menon B, Gullick NJ, Walter GJ, et al. Interleukin-17+CD8+T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. 2014;66: 1272-81.
11. Leijten EF, van Kempen TS, Boes M, et al. Brief report: Enrichment of activated group 3 innate lymphoid cells in psoriatic arthritis synovial fluid. Arthritis Rheumatol 2015;67: 2673-8.
12. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;386: 1137-46.
13. Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 2015;373: 1329-39.
14. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006;54: 2665-73.
15. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38: 727-35.
16. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;64(Suppl 2): Ii65-8; discussion ii69-73.
17. Weisman S, Pollack CR, Gottschalk RW. Psoriasis disease severity measures: Comparing efficacy of treatments for severe psoriasis. J Dermatolog Treat 2003;14: 158-65.
18. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23: 137-45.
19. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: The health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9: 789-93.
20. van der Heijde D, Sharp J, Wassenberg S, et al. Psoriatic arthritis imaging: A review of scoring methods. Ann Rheum Dis 2005;64(Suppl 2): Ii61-4.
21. Wells G, Becker JC, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68: 954-60.
22. Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008;59: 686-91.
23. Helliwell PS, Firth J, Ibrahim GH, et al. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J Rheumatol 2005;32: 1745-50.
24. Healy PJ, Helliwell PS. Measuring dactylitis in clinical trials: Which is the best instrument to use? J Rheumatol 2007;34: 1302-6.
25. Kimball AB, Naegeli AN, Edson-Heredia E, et al. Psychometric properties of the itch numeric rating scale in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2016;175: 157-62.
26. Rich P, Scher RK. Nail psoriasis severity index: A useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49: 206-12.
27. Mease PJ, Woolley JM, Bitman B, et al. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: Relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol 2011;38: 2461-5.
28. Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. Bethesda, MD: National Cancer Institute, 2006. http: //ctep.cancer.gov/protocolDevelopment/ electronic-applications/docs/ctcaev3.pdf (accessed 14 Jun 2010).
29. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366: 1190-9.
30. Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two phase 3 randomised trials. Lancet 2015;386: 541-51.
31. Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014;370: 2295-306.
32. Huang W, Na L, Fidel PL, et al. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 2004;190: 624-31.
33. Chimenti MS, Ballanti E, Perricone C, et al. Immunomodulation in psoriatic arthritis: Focus on cellular and molecular pathways. Autoimmun Rev 2013;12: 599-606.
34. Yamamoto T. Angiogenic and inflammatory properties of psoriatic arthritis. ISRN Dermatol 2013;2013: 630620.